Patents by Inventor Miriam Frieden

Miriam Frieden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligomeric compounds for the modulation of Bcl-2
    Patent number: 7622453
    Abstract: The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position No. 1459 (5?) to No. 1476 (3?) of the human Bcl-2 mRNA, said target binding domain having the formula: 5?-[(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3? and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (—O—P(O,S)—O—). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: November 24, 2009
    Assignee: Santaris Pharma A/S
    Inventors: Miriam Frieden, Jens B. Hansen, Henrik Orum, Majken Westergaard, Charlotte A. Thrue
  • OLIGONUCLEOTIDES WITH ALTERNATING SEGMENTS OF LOCKED AND NON-LOCKED NUCLEOTIDES
    Publication number: 20090209748
    Abstract: The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy.
    Type: Application
    Filed: November 18, 2003
    Publication date: August 20, 2009
    Inventors: Charlotte Albaek Thrue, Christoph Rosenbohm, Henrik Frydenlund Hansen, Majken Westergaard, Nikolaj Dam Mikkelsen, Signe Christensen, Troels Koch, Daniel Sejer Pedersen, Miriam Frieden
  • Antisense design
    Publication number: 20060128646
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: November 18, 2003
    Publication date: June 15, 2006
    Applicant: Santaris Pharma A/S
    Inventors: Signe Christensen, Nikolaj Mikkelsen, Miriam Frieden, Henrik Hansen, Troels Koch, Daniel Pedersen, Christoph Rosenbohm, Charlotte Thrue, Majken Westergaard
  • Oligomeric compounds for the modulation of Bcl-2
    Publication number: 20050203042
    Abstract: The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position No. 1459 (5?) to No. 1476 (3?) of the human Bcl-2 mRNA, said target binding domain having the formula: 5?-[(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3 and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (—O—P(O,S)—O—). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.
    Type: Application
    Filed: December 23, 2004
    Publication date: September 15, 2005
    Inventors: Miriam Frieden, Jens Hansen, Henrik Orum, Majken Westergaard, Charlotte Thrue